Blood Nesfatin-1 Levels in Patients with Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Feb 8

PMID 38327900

Authors

Mei Wang

Jiao Tong

Qing Zhu

Huaiyun Tang

Lisha Tang

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have investigated the relationship between nesfatin-1 level and polycystic ovary syndrome (PCOS). However, these studies have produced conflicting results. Thus, in this meta-analysis, we aimed to clarify the association between blood nesfatin-1 levels and PCOS, and the ability of nesfatin-1 as a biomarker in PCOS.

Methods: Meta-analysis was performed using STATA 12.0 software. We computed standard mean difference (SMD) and 95% confidence interval (CI) regarding the comparison of blood nesfatin-1 in patients with PCOS and controls.

Results: The present meta-analysis showed no significant difference in blood nesfatin-1 level between patients with PCOS and controls with a random effects model (SMD = 0.03; 95%CI: -0.71, 0.77; I 97.1%, value for Q test < 0.001). Subgroup analysis for different ethnicities reported no significant difference in blood nesfatin-1 level between patients with PCOS and controls in both Caucasian and Asian populations. Subgroup analysis for different sample types reported no significant difference in serum nesfatin-1 level between patients with PCOS and controls. Subgroup studies reported no significant difference in blood nesfatin-1 level between PCOS and controls in both obese and non-obese populations.

Conclusion: In conclusion, there is no significant relationship between blood nesfatin-1 levels and PCOS.

References

Dapas M, Dunaif A . Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification. Endocr Rev. 2022; 43(6):927-965. PMC: 9695127. DOI: 10.1210/endrev/bnac001. View

Varli B, Sukur Y, Ozmen B, Erguder B, Sonmezer M, Berker B . Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome. Clin Exp Reprod Med. 2021; 48(4):368-373. PMC: 8651756. DOI: 10.5653/cerm.2021.04420. View

Glueck C, Goldenberg N . Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2018; 92:108-120. DOI: 10.1016/j.metabol.2018.11.002. View

Witchel S, Teede H, Pena A . Curtailing PCOS. Pediatr Res. 2019; 87(2):353-361. DOI: 10.1038/s41390-019-0615-1. View

Kir Sahin F, Sahin S, Ural U, Cumhur Cure M, Senturk S, Bayoglu Tekin Y . Nesfatin-1 and Vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome. Bosn J Basic Med Sci. 2015; 15(3):57-63. PMC: 4594327. DOI: 10.17305/bjbms.2015.432. View

Gomez J, VanHise K, Stachenfeld N, Chan J, Merz N, Shufelt C . Subclinical cardiovascular disease and polycystic ovary syndrome. Fertil Steril. 2022; 117(5):912-923. PMC: 10322116. DOI: 10.1016/j.fertnstert.2022.02.028. View

Ranjan A, Choubey M, Yada T, Krishna A . Nesfatin-1 ameliorates type-2 diabetes-associated reproductive dysfunction in male mice. J Endocrinol Invest. 2019; 43(4):515-528. DOI: 10.1007/s40618-019-01136-0. View

Su Y, Zhang J, Tang Y, Bi F, Liu J . The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun. 2009; 391(1):1039-42. DOI: 10.1016/j.bbrc.2009.12.014. View

Altas M, Uca A, Akdag T, Odabas F, Serhat Tokgoz O . Serum levels of irisin and nesfatin-1 in multiple sclerosis. Arq Neuropsiquiatr. 2022; 80(2):161-167. PMC: 9648912. DOI: 10.1590/0004-282X-ANP-2020-0520. View

10.

Ademoglu E, Gorar S, Carlioglu A, Yazici H, Dellal F, Berberoglu Z . Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. J Endocrinol Invest. 2014; 37(8):715-719. DOI: 10.1007/s40618-014-0089-2. View

11.

Alp E, Gormus U, Guducu N, Bozkurt S . Nesfatin-1 levels and metabolic markers in polycystic ovary syndrome. Gynecol Endocrinol. 2015; 31(7):543-7. DOI: 10.3109/09513590.2015.1024219. View

12.

Kadoglou N, Korakas E, Lampropoulos S, Maratou E, Kassimis G, Patsourakos N . Plasma nesfatin-1 and DDP-4 levels in patients with coronary artery disease: Kozani study. Cardiovasc Diabetol. 2021; 20(1):166. PMC: 8362239. DOI: 10.1186/s12933-021-01355-x. View

13.

Farhangi M, Dehghan P, Tajmiri S, Mesgari Abbasi M . The effects of Nigella sativa on thyroid function, serum Vascular Endothelial Growth Factor (VEGF) - 1, Nesfatin-1 and anthropometric features in patients with Hashimoto's thyroiditis: a randomized controlled trial. BMC Complement Altern Med. 2016; 16(1):471. PMC: 5112739. DOI: 10.1186/s12906-016-1432-2. View

14.

Zhai T, Li S, Fan X, Tian Z, Lu X, Dong J . Circulating Nesfatin-1 Levels and Type 2 Diabetes: A Systematic Review and Meta-Analysis. J Diabetes Res. 2018; 2017:7687098. PMC: 5763168. DOI: 10.1155/2017/7687098. View

15.

Mirakhor Samani S, Ghasemi H, Rezaei Bookani K, Shokouhi B . SERUM NESFATIN-1 LEVEL IN HEALTHY SUBJECTS WITH WEIGHT-RELATED ABNORMALITIES AND NEWLY DIAGNOSED PATIENTS WITH TYPE 2 DIABETES MELLITUS; A CASE-CONTROL STUDY. Acta Endocrinol (Buchar). 2019; -5(1):69-73. PMC: 6535324. DOI: 10.4183/aeb.2019.69. View

16.

Konczol K, Bodnar I, Zelena D, Pinter O, Papp R, Palkovits M . Nesfatin-1/NUCB2 may participate in the activation of the hypothalamic-pituitary-adrenal axis in rats. Neurochem Int. 2010; 57(3):189-97. DOI: 10.1016/j.neuint.2010.04.012. View

17.

Szeliga A, Podfigurna A, Meczekalski B . Nesfatin-1 as a potential marker for functional hypothalamic amenorrhea. Gynecol Endocrinol. 2022; 38(11):992-996. DOI: 10.1080/09513590.2022.2126455. View

18.

Demir Caltekin M, Caniklioglu A, Yalcin S, Aydogan Kirmizi D, Baser E, Yalvac E . DLK1 and Nesfatin-1 levels and the relationship with metabolic parameters in polycystic ovary syndrome: Prospective, controlled study. Turk J Obstet Gynecol. 2021; 18(2):124-130. PMC: 8191326. DOI: 10.4274/tjod.galenos.2021.39024. View

19.

Konczol K, Pinter O, Ferenczi S, Varga J, Kovacs K, Palkovits M . Nesfatin-1 exerts long-term effect on food intake and body temperature. Int J Obes (Lond). 2012; 36(12):1514-21. DOI: 10.1038/ijo.2012.2. View

20.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View